» Articles » PMID: 33591842

Solid Tumor Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study

Overview
Publisher Sage Publications
Date 2021 Feb 16
PMID 33591842
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) occurs more frequently in cancer patients than in the general population. A retrospective cross-sectional study was carried out in patients with solid tumor complicated with VTE admitted to the Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 1st, 2008 and December 31th, 2017. The incidence of VTE in hospitalized cancer patients was 1.8%, twice the incidence of VTE in hospitalized non-cancer patients. The annual incidence of cancer-associated VTE in our center varied between 1.6% in 2015 and 0.4% in 2009 with an overall average incidence of 1.3% over the research decade. BMI values of 549(67.7%) cancer patients were within the normal range, but none of patients had BMI greater than 35 kg/m. 747(92.1%) cancer patients had ECOG PS score ≤ 2 and 481(59.3%) had distant metastasis. Patients with pancreatic, bladder, ovarian and endometrial cancer had the highest incidence of VTE. Upper extremity DVT (47.2%) was more common in cancer patients and might be closely associated with CVC (74.9%), while lower extremities DVT (36.1%) intended to PE development (15.0%). The annual incidence rates showed a fluctuating and upward trend over the research decade. VTE occurrence was closely related to tumor stage, tumor site, catheterization and anti-neoplasm therapy in cancer patients.

Citing Articles

Solid Tumors, Liquid Challenges: The Impact of Coagulation Disorders.

Shapoo N, Boma N, Chaudhari S, Gotlieb V Hematol Rep. 2025; 17(1).

PMID: 39997356 PMC: 11854944. DOI: 10.3390/hematolrep17010008.


Preoperative Systemic Immune-Inflammatory Index as a Predictive Biomarker for Lower Extremity Deep Vein Thrombosis after Breast Cancer Surgery: Stratified Nursing Intervention to Reduce Incidence.

Tian L, Zhu J, Li X, Huang L, Tian L Med Sci Monit. 2023; 29:e942087.

PMID: 38104239 PMC: 10734205. DOI: 10.12659/MSM.942087.


Profile of Solid Tumor Patients Complicated With Venous Thromboembolism: A 10-Year Retrospective Cross-Sectional Study Based on 1482 Cases.

Li H, Tian Y, Niu H, He L, Cao G, Zhang C Clin Appl Thromb Hemost. 2023; 29:10760296231169514.

PMID: 37062945 PMC: 10116012. DOI: 10.1177/10760296231169514.


Prevalence and treatment of venous thromboembolism in patients with solid tumors.

Zhao H, Liang F, Ling Y, Li T, Fang B, Deng T Exp Ther Med. 2022; 24(6):743.

PMID: 36478882 PMC: 9716337. DOI: 10.3892/etm.2022.11679.


Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.

Li H, Tian Y, Niu H, He L, Cao G, Zhang C Front Oncol. 2022; 12:988287.

PMID: 36300098 PMC: 9589115. DOI: 10.3389/fonc.2022.988287.


References
1.
Lee A, Levine M . Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003; 107(23 Suppl 1):I17-21. DOI: 10.1161/01.CIR.0000078466.72504.AC. View

2.
Yust-Katz S, Mandel J, Wu J, Yuan Y, Webre C, Pawar T . Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015; 124(1):87-94. DOI: 10.1007/s11060-015-1805-2. View

3.
Timp J, Braekkan S, Versteeg H, Cannegieter S . Epidemiology of cancer-associated venous thrombosis. Blood. 2013; 122(10):1712-23. DOI: 10.1182/blood-2013-04-460121. View

4.
Zuurbier S, Arnold M, Middeldorp S, Broeg-Morvay A, Silvis S, Heldner M . Risk of Cerebral Venous Thrombosis in Obese Women. JAMA Neurol. 2016; 73(5):579-84. DOI: 10.1001/jamaneurol.2016.0001. View

5.
Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Buller H . Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost. 2010; 104(5):1049-54. DOI: 10.1160/TH10-05-0277. View